Triterpenes are a large family of bitter-tasting compounds found in the reishi mushroom (Ganoderma lucidum), and ganoderic acids are the specific triterpenes unique to reishi. Along with beta-glucan polysaccharides, triterpenes are considered one of reishi’s two headline bioactive compound groups. Researchers have identified numerous distinct triterpenes in reishi, including several named ganoderic acids, and laboratory and animal research links this compound family to anti-inflammatory and hepatoprotective (liver-protective) activity, though human clinical evidence for most of these specific effects remains limited.
Important Safety Information First
Before looking at the research on triterpenes, two safety points deserve attention because they involve real, documented harm.
- Liver injury has been reported with reishi, especially powdered forms. Case reports in medical literature describe acute hepatitis and, in at least one instance, fatal liver failure linked to powdered reishi mushroom or reishi extract. A 2023 case report also described acute liver injury in a person who combined reishi powder with alcohol.
- Reishi can increase bleeding risk. Reishi extracts may prolong blood-clotting lab values (INR, PT, and APTT), and case reports describe increased bleeding risk in people taking blood thinners such as warfarin.
Anyone taking blood thinners, anyone with a liver condition, and anyone combining reishi with alcohol or other supplements should talk with a clinician before use. This is general education, not a recommendation to use, avoid, start, or stop any product.
The Two Main Bioactive Compound Families in Reishi
Reishi’s research literature generally separates its activity into two compound classes, based on a clinical evidence summary published by Memorial Sloan Kettering Cancer Center’s (MSK) Integrative Medicine service.
- Beta-glucan polysaccharides: complex sugar chains extracted mainly with hot water. In cell and animal studies, these have shown immune-modulating and antitumor activity.
- Triterpenes, including ganoderic acids: bitter-tasting compounds extracted more efficiently with alcohol. In cell and animal studies, these have shown anti-inflammatory, hepatoprotective, and renoprotective (kidney-protective) activity, and some ganoderic acids may reduce cancer cell invasion by lowering matrix metalloproteinase expression.
MSK’s summary describes both compound families as active “both in vitro and in vivo” — meaning in laboratory cell cultures and in animal studies. This is preclinical evidence. It is a useful signal for how a compound might behave, but it does not confirm the same effect happens in humans at typical supplement doses.
How Extraction Method Affects Triterpene Content
Not all reishi products contain the same amount of triterpenes, because how the mushroom is processed changes what ends up in the final extract:
- Hot-water extraction pulls out more of the water-soluble beta-glucan polysaccharides.
- Alcohol (ethanol) extraction pulls out more of the triterpenes and ganoderic acids, which are less water-soluble.
- Dual extraction (using both water and alcohol) is intended to capture both compound families in a single product.
Because reishi products also vary in species and growing conditions, the specific triterpene content of any two products can differ substantially. A DNA analysis of commercial reishi products found that most were derived from a species now classified as Ganoderma lingzhi rather than Ganoderma lucidum in the strict scientific sense, which is one more reason product-to-product comparisons on triterpene content are difficult to make from general research alone.
What the Human Evidence Actually Shows
Separating human clinical trial data from lab and animal data is important, because reishi’s traditional reputation is much broader than what controlled human research currently supports.
Where small human trials have shown a signal:
- A randomized, placebo-controlled trial found reishi extract improved lower urinary tract symptoms in men.
- Small controlled studies found reishi increased plasma antioxidant capacity and produced mild improvements in blood sugar and lipid measures in some participants.
- A cross-sectional survey of cancer patients found many participants reported improvement in nausea, fatigue, appetite, and low mood while using reishi, though this type of study cannot establish that reishi caused the improvement.
Where randomized controlled trials did not support a benefit:
- A Cochrane systematic review of randomized controlled trials found reishi did not meaningfully reduce cardiovascular risk factors related to type 2 diabetes.
- A separate randomized trial found reishi did not improve blood or body composition measures in people with fibromyalgia.
- A pilot study of reishi spore powder did not find benefit for Alzheimer’s disease symptoms.
- A 2016 Cochrane review focused specifically on reishi as a cancer treatment concluded there was not enough high-quality evidence to support its use as an adjunct cancer therapy, despite immune-related laboratory findings.
- MedlinePlus, a National Institutes of Health consumer health resource, rates reishi as “possibly ineffective” for lowering cholesterol levels in people with diabetes or high cholesterol.
Most of the anti-inflammatory and hepatoprotective claims tied specifically to triterpenes and ganoderic acids come from cell and animal research rather than controlled human trials. That does not mean the findings are meaningless — it means they represent an early stage of evidence, not a confirmed human health benefit.
Evidence Limits
- Most triterpene-specific anti-inflammatory and hepatoprotective data comes from laboratory and animal studies, not human trials.
- Commercial reishi products vary widely in species, plant part used, and extraction method, so findings from one study’s extract may not apply to a different product.
- Several of the human trials that do exist are small, and some outcomes, like general wellbeing improvements in cancer patients, come from self-reported surveys rather than blinded, controlled comparisons.
- Reishi mushroom spore powder has been shown to falsely elevate a cancer-related lab marker (CA72-4), which could complicate cancer monitoring for people using it.
Who Should Use Extra Caution
- People taking blood thinners or antiplatelet medications, due to documented bleeding risk.
- People with existing liver conditions, or anyone combining reishi with alcohol, given documented case reports of liver injury.
- People taking immunosuppressant medications, since reishi may stimulate immune activity.
- People who are pregnant or breastfeeding — MedlinePlus notes there is not enough reliable safety information and recommends avoiding use.
- People being monitored with cancer-related blood tests, due to the CA72-4 interference noted above with spore powder specifically.
Anyone in these groups, or anyone considering reishi for a health condition, should talk with a qualified clinician before starting, stopping, or changing use.
Frequently Asked Questions
Are ganoderic acids the same thing as triterpenes?
Ganoderic acids are a specific group of triterpenes found in reishi. All ganoderic acids are triterpenes, but not all reishi triterpenes are classified as ganoderic acids — triterpenes is the broader compound family.
Do triterpenes make reishi taste bitter?
Reishi’s pronounced bitterness is often attributed to its triterpene content, which is one reason reishi is usually taken as a capsule, extract, or tea rather than eaten as a food mushroom.
Is reishi safe to take every day?
This depends on the individual, the product, and how long it’s used, and it is a question for a clinician rather than a general article. MedlinePlus notes that reishi extract is considered possibly safe for up to one year of use and powdered whole reishi for up to 16 weeks, based on available safety data, but this is not personal medical guidance.
Can triterpenes in reishi help with cancer?
Laboratory research has found that some reishi triterpenes may reduce cancer cell invasion in cell studies, and some small human studies have looked at reishi alongside cancer care. However, a 2016 Cochrane systematic review concluded there is not enough high-quality clinical trial evidence to support reishi as a cancer treatment, and it should never replace or delay medical cancer treatment. Anyone with cancer should discuss any supplement use with their oncology team first.
Educational Disclaimer
This article is for general educational purposes only and is not medical advice. It does not diagnose any condition, recommend any product, or suggest that anyone start, stop, or change a medication or supplement. Evidence on reishi triterpenes and ganoderic acids differs by study design, extraction method, and population studied. Anyone considering reishi, especially those taking medication, managing a liver condition, or pregnant or breastfeeding, should speak with a qualified clinician first. For more on how claims on this site are evaluated, see our evidence grading and source policy, our editorial standards, and our full medical disclaimer.